Pharmacoeconomic review report Semaglutide (Ozempic), (Novo Nordisk Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Cost effectiveness.

Physical Description:

1 online resource (38 pages) : illustrations.

Edition:

Final (with redactions).

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2019.

Summary:

Semaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist injection, indicated for the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control. The manufacturer is seeking reimbursement of semaglutide: in patients with type 2 diabetes mellitus either in combination with metformin for patients who have not achieved adequate glycemic control with metformin alone (second-line treatment), or in combination with metformin plus sulfonylurea for patients who have not achieved adequate glycemic control with metformin in combination with sulfonylurea (third-line treatment). The starting dose of semaglutide is 0.25 mg once weekly. After four weeks, the dose should be increased to 0.5 mg once weekly. After an additional week, the dose can be increased to 1 mg once weekly. The manufacturer submitted a cost-utility analysis over a 40-year time horizon (the manufacturer suggests that this is essentially a lifetime horizon, from the perspective of a Canadian public health care payer).

Notes:

Includes bibliographical references.

Description based on publisher supplied metadata and other sources.